FFO
LXRX icon

Fortitude Family Office’s Lexicon Pharmaceuticals LXRX Stock Holding History

Fortitude Family Office’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.32K Hold
706
– – ﹤0.01% 2149
2026
Q2 		$1.69K Hold
706
– – ﹤0.01% 1541
2026
Q1 		$1.1K Hold
706
– – ﹤0.01% 1484
2025
Q4 		$812 Hold
706
– – ﹤0.01% 1539
2025
Q3 		$953 Hold
706
– – ﹤0.01% 1562
2025
Q2 		$668 Buy
+706
New +$457 ﹤0.01% 1674

Other funds holding LXRX

SFL
Scheeler Financial LLC West Chester, Ohio $132M AUM
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
MassMutual Private Wealth & Trust
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Fortitude Family Office's LXRX Position: Q3 2026 in Review

Fortitude Family Office held its Lexicon Pharmaceuticals (LXRX) position steady in Q3 2026 at 706 shares worth $1.32K. The position accounts for ﹤0.01% of the portfolio, ranked #2149.

Fortitude Family Office first reported a position in LXRX in Q2 2025 and has held it in 6 quarters since. The position peaked at $1.69K in Q2 2026. 6 funds tracked by Wall St. Rank hold LXRX as of Q3 2026.

  • Fortitude Family Office held 706 shares of Lexicon Pharmaceuticals worth $1.32K as of Q3 2026.
  • Fortitude Family Office left its Lexicon Pharmaceuticals share count unchanged in Q3 2026.
  • Lexicon Pharmaceuticals made up ﹤0.01% of Fortitude Family Office's portfolio in Q3 2026, its #2149 holding.
  • Fortitude Family Office first reported a position in Lexicon Pharmaceuticals in Q2 2025 and has held it in 6 quarters since.
  • Fortitude Family Office's Lexicon Pharmaceuticals position peaked at $1.69K in Q2 2026.
  • 6 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q3 2026.

Based on Fortitude Family Office's 13F filing for Q3 2026, filed 14 Oct 2026.